Catestatin suppresses melanoma progression and drug resistance through multitargeted modulation of signaling pathways.

ABSTRACT:

Background

Despite advances in targeted and immune-based therapies, melanoma remains one of the most aggressive and treatment-resistant cancers. Resistance to small-molecule inhibitors and immune checkpoint blockade highlights the need for new mechanistically distinct interventions. Catestatin (CST), a Chromogranin A (CgA)-derived peptide with immunomodulatory and reparative properties, has been implicated in tissue protection, but its role in melanoma remains unknown.

Methods

CST expression was analyzed across melanoma stages and correlated with disease progression. Functional effects of CST were assessed in patient-derived and established melanoma cell lines, as well as in B16-F10 melanoma-bearing mice. RNA sequencing and pathway analyses were performed to delineate CST-re

SUBMITTER: Kal S 

PROVIDER: S-EPMC12633551 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature